Straits Times Index
3,248.79 -15.74 (-0.48%) Nikkei
38,357.82 +155.45 (+0.41%) Hang Seng
18,385.20 +71.34 (+0.39%) FTSE 100
8,354.05 +40.38 (+0.49%) Bitcoin USD
61,636.89 -1,143.89 (-1.82%) CMC Crypto 200
1,311.34 +16.67 (+1.29%)
Genmab A/S (GNMSF)
| Previous close | 283.92 |
| Open | 293.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 274.16 - 293.89 |
| 52-week range | 262.00 - 426.50 |
| Volume | |
| Avg. volume | 1,001 |
| Market cap | 18.645B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 23.20 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript May 2, 2024 Genmab A/S reports earnings inline with expectations. Reported EPS is $0.16 EPS, expectations were $0.16. Genmab A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to […]
- GuruFocus.com
Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
Explore key insights from Comstock Inc's Q1 2024 earnings, including significant revenue streams, strategic investments, and future financial strategies.
- Reuters
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
The acquisition will give Genmab worldwide rights to three candidates in clinical development, they said. Genmab shares were down 1.7% at 0955 GMT. Jyske bank analyst Henrik Hallengreen Laustsen said that while the acquisition is seen as slightly positive for Genmab shares, the price is difficult to assess, and added it might be "a bit high".
